Previous 10 | Next 10 |
Gainers: Tenax Therapeutics (TENX) +132%, Regional Health Properties (RHE) +38%, IRIDEX (IRIX) +22%, INmune Bio (INMB) +17%, Mirum Pharmaceuticals (MIRM) +8%.Losers: Arcturus Therapeutics (ARCT) -53%, Actinium Pharmaceuticals (ATNM) -24%, Alpine Immune ...
After sharp losses in post-market trading yesterday, Arcturus Therapeutics (ARCT) keeps falling in pre-market today in above-average volume as Wall Street downgrades the company following the update for its COVID-19 vaccine candidate yesterday. The analysts from Barclays,...
Arcturus Therapeutics (ARCT) -38% after vaccine data update.Monaker Group (MKGI) -30% after announcing $6.5M bought deal offering.AeroCentury (ACY) -26% despite NYSE acceptance of regaining listing compliance.Magal Security Systems (MAGS) -20%.Ameri Holdings...
Gainers: [[UUU]] +71.2%. [[IRIX]] +28.6%. [[XGN]] +10.6%. [[CANG]] +10.5%. [[MIRM]] +6.4%.Losers: [[ARCT]] -35.3%. [[ACY]] -23.3%. [[AIRT]] -8.8%. [[RHE]] -7.6%. [[RCMT]] -6.2%. For further details see: UUU, ACY, IRIX, and ARCT among after-hours movers
Arcturus Therapeutics (ARCT) is down 35.0% in after-hours as the company provided the clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021. Arcturus also announced that the Singapore Health Sciences Authority has signed off its Phase 2 clinical s...
Phase 1/2 data demonstrates favorable tolerability; immunogenicity observed in 100% (44/44) of vaccinated subjects receiving 7.5 µg single dose & 5 µg single and prime-boost regimens In primate challenge model, ARCT-021 demonstrates protection following both sing...
Arcturus Therapeutics ([[ARCT]] -10.3%) price affected after double downgraded after Roth Capital analyst Elemer Piros to Sell from Buy.While there could be a number of advantages to Arcturus' Covid vaccine, including a lower dose, potential single dose and storage advantage, the efficacy bar...
Shares of Arcturus Therapeutics (NASDAQ: ARCT) were sinking 8.4% as of 10:49 a.m. EST on Wednesday. The decline came after Roth Capital analyst Elemer Piros downgraded Arcturus from buy to sell. It's best not to place too much emphasis on analysts' downgrades (or upgrades). Howe...
Many of the best stocks in 2020 were healthcare companies focused on two disease areas: trying to stop the spread of COVID-19 and improving survival rates from deadly diseases. Their scientific achievements have been nothing less than extraordinary. By looking at healthcare companies with m...
Are These The Best Biotech Stocks To Watch This Week? Biotech stocks have been riding a wave of success in the stock market this year. Investors looking for high growth investments have been paying attention to top biotech stocks in the last few months. The biotech indus...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...